Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KA27 001

Next Previous
X
Search
Drug Profile

KA27 001

Alternative Names: anti-CD27 agonist mAb - Kineta; anti-CD27 mAbs - Kineta; anti-CD27 monoclonal antibodies - Kineta; Anti-CD27 monoclonal antibody - Kineta; KA27-001; αCD27 mAbs; αCD27 monoclonal antibodies - Kineta

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GigaGen
  • Developer Kineta
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued Haematological malignancies

Most Recent Events

  • 08 May 2024 Kineta has patent protection for KA27 001
  • 04 Oct 2023 Data from a preclinical study in Solid tumours released by Kineta
  • 05 Apr 2023 Kineta plans a phase I trial for Solid tumours (Late-stage disease) in USA in second half of 2024 (Kineta pipeline, April 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top